FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4280528654> ?p ?o ?g. }

• W4280528654 endingPage "97" @default.
• W4280528654 startingPage "85" @default.
• W4280528654 abstract "Objective: to study the seroprevalence of SARS-CoV-2 antibodies (AB) in children in the 2nd year of the COVID-19 pandemic in Russia. Materials and methods: prospective cohort study. The seroprevalence research was conducted among 3670 children aged 1 to 17 y/o from 26 modelling regions of Russia (that have been participating earlier in the five stages of seromonitoring during 2020-2021). The serological testing was carried out in December, 2021. The work was carried out according to a unified methodology set by the Russian Federal Service for Supervision of Consumer Rights Protection and Human Well-Being with the Pasteur Institute of Epidemiology and Microbiology (Saint Petersburg, Russia). The plasma was obtained from 3 ml of venous blood, in which the level of AB to nucleocapsid (NC), and the SARS-CoV-2 receptor-binding domain (RBD) was determined by immunoferment method using reagents for qualitative and quantitative analysis. Results: the analysis of AB seroprevalence to NC and RBD showed the statistically significant increase in the share of seropositivity to RBD in children of all modelling regions (p<0.05). The most seropositive volunteers contained low levels of AB: 31.3-125.6 BAU/ml NC and 22.6-220 BAU/ml RBD. An increase in the level of AB to NC and RBD was accompanied by a decrease in the percentage of seropositive patients. Evaluating the contribution of children to the level of humoral immunity, convalescents (had been ill shortly before the examination), the “anamnesis” (had been ill at previous stages of seromonitoring) and asymptomatic (had been asymptomatically ill) groups were distinguished. The maximum contribution was made by children with asymptomatic cases of COVID-19 in anamnesis: in 82.3% (95% CI 81.1-83.6), of which 76.9% (95% CI 75.5-78.3) AB detected to RBD. The contribution of children of two other groups to the overall level of humoral immunity was 33 times less. Conclusion: statistically significant predominance of AB to RBD above AB to NC and their main contribution to the level of humoral immunity to SARS-CоV-2 (p<0.001)." @default.
• W4280528654 created "2022-05-22" @default.
• W4280528654 creator A5000250376 @default.
• W4280528654 creator A5000880755 @default.
• W4280528654 creator A5002384870 @default.
• W4280528654 creator A5002669716 @default.
• W4280528654 creator A5003288017 @default.
• W4280528654 creator A5007222608 @default.
• W4280528654 creator A5007748781 @default.
• W4280528654 creator A5010201781 @default.
• W4280528654 creator A5010795117 @default.
• W4280528654 creator A5012234324 @default.
• W4280528654 creator A5015927612 @default.
• W4280528654 creator A5016452932 @default.
• W4280528654 creator A5016698027 @default.
• W4280528654 creator A5020168719 @default.
• W4280528654 creator A5020415629 @default.
• W4280528654 creator A5020763673 @default.
• W4280528654 creator A5021883799 @default.
• W4280528654 creator A5022050940 @default.
• W4280528654 creator A5022522902 @default.
• W4280528654 creator A5026725209 @default.
• W4280528654 creator A5028342345 @default.
• W4280528654 creator A5033744935 @default.
• W4280528654 creator A5034708464 @default.
• W4280528654 creator A5035098198 @default.
• W4280528654 creator A5036089101 @default.
• W4280528654 creator A5037623555 @default.
• W4280528654 creator A5040303191 @default.
• W4280528654 creator A5042385446 @default.
• W4280528654 creator A5047833158 @default.
• W4280528654 creator A5049794003 @default.
• W4280528654 creator A5055168792 @default.
• W4280528654 creator A5066777084 @default.
• W4280528654 creator A5070578975 @default.
• W4280528654 creator A5073615937 @default.
• W4280528654 creator A5073963376 @default.
• W4280528654 creator A5075908456 @default.
• W4280528654 creator A5082117617 @default.
• W4280528654 creator A5082306817 @default.
• W4280528654 creator A5086610384 @default.
• W4280528654 creator A5087572738 @default.
• W4280528654 creator A5091284551 @default.
• W4280528654 date "2022-06-17" @default.
• W4280528654 modified "2023-09-27" @default.
• W4280528654 title "SERPENCELESSNESS OF ANTIBODIES TO SARS-CoV-2 IN CHILDREN AGAINST THE BACKGROUND OF THE COVID-19 EPIDEMIC IN THE RUSSIAN FEDERATION" @default.
• W4280528654 doi "https://doi.org/10.24110/0031-403x-2022-101-3-85-97" @default.
• W4280528654 hasPublicationYear "2022" @default.
• W4280528654 type Work @default.
• W4280528654 citedByCount "2" @default.
• W4280528654 countsByYear W42805286542023 @default.
• W4280528654 crossrefType "journal-article" @default.
• W4280528654 hasAuthorship W4280528654A5000250376 @default.
• W4280528654 hasAuthorship W4280528654A5000880755 @default.
• W4280528654 hasAuthorship W4280528654A5002384870 @default.
• W4280528654 hasAuthorship W4280528654A5002669716 @default.
• W4280528654 hasAuthorship W4280528654A5003288017 @default.
• W4280528654 hasAuthorship W4280528654A5007222608 @default.
• W4280528654 hasAuthorship W4280528654A5007748781 @default.
• W4280528654 hasAuthorship W4280528654A5010201781 @default.
• W4280528654 hasAuthorship W4280528654A5010795117 @default.
• W4280528654 hasAuthorship W4280528654A5012234324 @default.
• W4280528654 hasAuthorship W4280528654A5015927612 @default.
• W4280528654 hasAuthorship W4280528654A5016452932 @default.
• W4280528654 hasAuthorship W4280528654A5016698027 @default.
• W4280528654 hasAuthorship W4280528654A5020168719 @default.
• W4280528654 hasAuthorship W4280528654A5020415629 @default.
• W4280528654 hasAuthorship W4280528654A5020763673 @default.
• W4280528654 hasAuthorship W4280528654A5021883799 @default.
• W4280528654 hasAuthorship W4280528654A5022050940 @default.
• W4280528654 hasAuthorship W4280528654A5022522902 @default.
• W4280528654 hasAuthorship W4280528654A5026725209 @default.
• W4280528654 hasAuthorship W4280528654A5028342345 @default.
• W4280528654 hasAuthorship W4280528654A5033744935 @default.
• W4280528654 hasAuthorship W4280528654A5034708464 @default.
• W4280528654 hasAuthorship W4280528654A5035098198 @default.
• W4280528654 hasAuthorship W4280528654A5036089101 @default.
• W4280528654 hasAuthorship W4280528654A5037623555 @default.
• W4280528654 hasAuthorship W4280528654A5040303191 @default.
• W4280528654 hasAuthorship W4280528654A5042385446 @default.
• W4280528654 hasAuthorship W4280528654A5047833158 @default.
• W4280528654 hasAuthorship W4280528654A5049794003 @default.
• W4280528654 hasAuthorship W4280528654A5055168792 @default.
• W4280528654 hasAuthorship W4280528654A5066777084 @default.
• W4280528654 hasAuthorship W4280528654A5070578975 @default.
• W4280528654 hasAuthorship W4280528654A5073615937 @default.
• W4280528654 hasAuthorship W4280528654A5073963376 @default.
• W4280528654 hasAuthorship W4280528654A5075908456 @default.
• W4280528654 hasAuthorship W4280528654A5082117617 @default.
• W4280528654 hasAuthorship W4280528654A5082306817 @default.
• W4280528654 hasAuthorship W4280528654A5086610384 @default.
• W4280528654 hasAuthorship W4280528654A5087572738 @default.
• W4280528654 hasAuthorship W4280528654A5091284551 @default.
• W4280528654 hasConcept C106192422 @default.
• W4280528654 hasConcept C107130276 @default.
• W4280528654 hasConcept C126322002 @default.
• W4280528654 hasConcept C144024400 @default.
• W4280528654 hasConcept C149923435 @default.

• next